View in EDS

The α-glucosidase inhibitor acarbose reduces the net electronegative charge of low-density lipoprotein in patients with newly diagnosed type 2 diabetes

Saved in:
Bibliographic Details
Title: The α-glucosidase inhibitor acarbose reduces the net electronegative charge of low-density lipoprotein in patients with newly diagnosed type 2 diabetes
Authors: Hasegawa, Goji1 goji@koto.kpu-m.ac.jp, Kajiyama, Shizuo2, Tanaka, Toru3, Imai, Saeko4, Kozai, Hana4, Fujinami, Aya5, Ohta, Mitsuhiro5, Obayashi, Hiroshi6, Park, Hyohun1, Nakano, Koji1, Tanaka, Muhei1, Shiraishi, Emi1, Fukui, Michiaki1, Yoshikawa, Toshikazu1, Nakamura, Naoto1
Source: Clinica Chimica Acta. Apr2008, Vol. 390 Issue 1/2, p110-114. 5p.
Subjects: Hyperglycemia, Cardiovascular diseases risk factors, Type 2 diabetes, Glucosidase inhibitors
Abstract: Abstract: Background: Several epidemiological studies have shown that postprandial hyperglycemia is associated with an increased risk of cardiovascular disease (CVD). The present study was conducted in order to compare the effects of acarbose and glimepiride treatment on serum lipoprotein profiles in patients with type 2 diabetes. Methods: A total of 37 patients with newly diagnosed type 2 diabetes were studied. The patients were assigned randomly to treatment for 12 weeks with either acarbose (n =13, 100 mg×3/day, group A), glimepiride (n =13, 2 mg/day, group G) or diet only (n =11, group D). Lipid and lipoprotein profiles before and after each treatment were evaluated. Results: A significant reduction in the net electronegative charge of low-density lipoprotein (emLDL) was observed in group A (−1.8, P <0.01), whereas no significant change in emLDL was observed in groups G and D. In group A, small VLDL and very small LDL levels were also decreased significantly (P <0.05). The change in emLDL levels correlated significantly with changes in very small LDL (r =0.751, P <0.01) and oxidized LDL levels (r =0.623, P <0.05). Conclusion: These results suggest that measurement of serum emLDL may be a sensitive and clinically useful marker for determining qualitative lipoprotein abnormalities in diabetes, and that acarbose treatment lowers CVD risk by decreasing production of emLDL. [Copyright &y& Elsevier]
Copyright of Clinica Chimica Acta is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
Description
Abstract:Abstract: Background: Several epidemiological studies have shown that postprandial hyperglycemia is associated with an increased risk of cardiovascular disease (CVD). The present study was conducted in order to compare the effects of acarbose and glimepiride treatment on serum lipoprotein profiles in patients with type 2 diabetes. Methods: A total of 37 patients with newly diagnosed type 2 diabetes were studied. The patients were assigned randomly to treatment for 12 weeks with either acarbose (n =13, 100 mg×3/day, group A), glimepiride (n =13, 2 mg/day, group G) or diet only (n =11, group D). Lipid and lipoprotein profiles before and after each treatment were evaluated. Results: A significant reduction in the net electronegative charge of low-density lipoprotein (emLDL) was observed in group A (−1.8, P <0.01), whereas no significant change in emLDL was observed in groups G and D. In group A, small VLDL and very small LDL levels were also decreased significantly (P <0.05). The change in emLDL levels correlated significantly with changes in very small LDL (r =0.751, P <0.01) and oxidized LDL levels (r =0.623, P <0.05). Conclusion: These results suggest that measurement of serum emLDL may be a sensitive and clinically useful marker for determining qualitative lipoprotein abnormalities in diabetes, and that acarbose treatment lowers CVD risk by decreasing production of emLDL. [Copyright &y& Elsevier]
ISSN:00098981
DOI:10.1016/j.cca.2008.01.005